Stéphane de Botton

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.5K citations · Full text

Medicine, Hematology, Oncology +13

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Jeremy Travins, Byron DeLaBarre et al. · Science · 2013 · 797 citations

Medicine, Cancer Biology, Oncology +10

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

Claude Preudhomme, C. Sagot, Nicolas Boissel et al. · Blood · 2002 · 503 citations · Full text

Medicine, Hematology, Oncology +15

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Pau Montesinos, Christian Récher, Susana Vives et al. · New England Journal of Medicine · 2022 · 483 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10